First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

被引：0
|
作者：
Djelila Allouache
Sulochana R Gawande
Michele Tubiana-Hulin
Nicole Tubiana-Mathieu
Sophie Piperno-Neumann
Fawzia Mefti
Laurence Bozec
Jean-Yves Genot
机构：
[1] Lion sur mer,Centre F. Baclesse
[2] Lilly Corporate,Eli Lilly and Company
[3] Ctr René Huguenin,undefined
[4] Hopital Dupuytren,undefined
[5] Hospital Curie,undefined
[6] Lilly France,undefined
来源：
BMC Cancer | / 5卷
关键词：
Paclitaxel; Gemcitabine; Metastatic Breast Cancer; Anthracyclines; Inflammatory Breast Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
    Hope S. Rugo
    Mario Campone
    Dino Amadori
    Daniela Aldrighetti
    PierFranco Conte
    Andrew Wardley
    Cristian Villanueva
    Michelle Melisko
    M. Brent McHenry
    David Liu
    Francis Lee
    Xavier Pivot
    Breast Cancer Research and Treatment, 2013, 139 : 411 - 419
  • [32] Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure
    Demiray, M
    Kurt, E
    Evrensel, T
    Kanat, O
    Arslan, M
    Saraydaroglu, O
    Ercan, K
    Gonullu, G
    Gokgoz, S
    Topal, U
    Tolunay, S
    Tasdelen, I
    Manavoglu, O
    CANCER INVESTIGATION, 2005, 23 (05) : 386 - 391
  • [33] Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial
    Xu, Binghe
    Jiang, Zefei
    Kim, Sung-Bae
    Yu, Shiying
    Feng, Jifeng
    Malzyner, Artur
    del Giglio, Auro
    Chung, Hyun C.
    Shen, Li Jun
    Pen, Daniel Lee Kay
    BREAST CANCER, 2011, 18 (03) : 203 - 212
  • [34] Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
    L Manso
    E Ciruelos
    M Codes
    J De la Haba
    A Galan
    J Baena
    A Jaen
    M Gil
    A Murias
    I Blancas
    E Gonzalez
    D Perez
    JL Bayo
    J Mel
    E Garcia-Martinez
    R Cubedo
    J Salvador
    Breast Cancer Research, 13
  • [35] A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
    Yun, Tak
    Kim, Heung Tae
    Han, Ji-Youn
    Yoon, Sung Jin
    Kim, Hyae Young
    Nam, Byung-Ho
    Lee, Jin Soo
    CANCER RESEARCH AND TREATMENT, 2016, 48 (02): : 465 - 472
  • [36] Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer
    Delfino, C
    Caccia, G
    Gonzáles, LR
    Mickiewicz, E
    Rodger, J
    Balbiani, L
    Morales, DF
    Comba, AZ
    Brosio, C
    ONCOLOGY, 2004, 66 (01) : 18 - 23
  • [37] Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxel and gemcitabine as first-line therapy
    Manso, L.
    Ciruelos, E.
    Codes, M.
    De la Haba, J.
    Galan, A.
    Baena, J.
    Jaen, A.
    Gil, M.
    Murias, A.
    Blancas, I.
    Gonzalez, E.
    Perez, D.
    Bayo, J. L.
    Mel, J.
    Garcia-Martinez, E.
    Cubedo, R.
    Salvador, J.
    BREAST CANCER RESEARCH, 2011, 13
  • [38] Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer
    Murad, AM
    Guimaraes, RC
    Aragao, BC
    Scalabrini-Neto, AO
    Rodrigues, VH
    Garcia, R
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03): : 264 - 268
  • [39] Review of gemcitabine plus taxane combination therapy in the first-line treatment of metastatic breast cancer
    Colomer, Ramon
    EJC SUPPLEMENTS, 2008, 6 (04): : 9 - 12
  • [40] Paclitaxel and doxorubicin combination in the first-line treatment of metastatic breast cancer
    Baltali, E
    Altundag, MK
    Güler, N
    Özisik, Y
    Firat, D
    Baran, I
    Tekuzman, G
    TUMORI, 2002, 88 (03) : 200 - 203
12345